Northwestern Medicine investigators have discovered a new combination approach that may improve the efficacy of MYC inhibitor drugs for treating aggressive and treatment-resistant cancers, according to a recent Northwestern Medicine study published in Science Advances.

A newly discovered inhibitor of a common cancer-causing protein operates selectively, reducing expression of genes that fuel rampant cell proliferation, and altering the epigenome, according to a recent study.

A novel integrative computational technique allowed scientists to classify disease conditions at the molecular level using epigenomic data sets.

A recent Northwestern Medicine study has identified that a transcription factor protein called AP-1 regulates gene enhancers that may be responsible for promoting the development of uterine fibroids.